

Value IN HEALTH

VOLUME 16

NUMBER 5

JULY/AUGUST 2013

TABLE OF CONTENTS

COMMENTARY

- 699 How Should We Value Future Health? Was NICE Right to Change?**

James Raftery

EDITORIAL

- 701 Where Are We on “Risk-Sharing” Agreements?**

Peter J. Neumann

ISPOR TASK FORCE REPORT

- 703 Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force**

Louis P. Garrison Jr., Adrian Towse, Andrew Briggs, Gerard de Pouvourville, Jens Grueger, Penny E. Mohr, J.L. (Hans) Severens, Paolo Siviero, and Miguel Sleeper

ORIGINAL RESEARCH***Economic Evaluation***

- 720 Value of Research and Value of Development in Early Assessments of New Medical Technologies**

Valesca P. Retèl, Janneke P.C. Grutters, Wim H. van Harten, and Manuela A. Joore

- 729 Cost-Effectiveness of the 21-Gene Assay for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer**

Mike Paulden, Jacob Franek, Ba' Pham, Philippe L. Bedard, Maureen Trudeau, and Murray Krahn

- 740 Compensation Mechanisms for Lost Productivity: A Comparison between Four European Countries**

S. Knies, A. Boonen, M.J.J.M. Candel, S.M.A.A. Evers, and J.L. Severens

- 745 Economic Analysis of the Intangible Impacts of Informal Care for People with Alzheimer's Disease and Other Mental Disorders**

Chloé Gervès, Martine Marie Bellanger, and Joël Ankri

- 755 Potential Cost-Effectiveness of Pneumococcal Conjugate Vaccine (PCV) in Turkey**

Özden Türel, Adnan Kisa, E. David G. McIntosh, and Mustafa Bakir

- 760 Transarterial Chemoembolization Treatment: Association between Multiple Treatments, Cumulative Expenditures, and Survival**

Ian M. Breunig, Fadia T. Shaya, Nader Hanna, Brian Seal, Viktor V. Chirikov, and C. Daniel Mullins

- 769 Gastroprotective Strategies in Chronic NSAID Users: A Cost-Effectiveness Analysis Comparing Single-Tablet Formulations with Individual Components**

N.L. de Groot, B.M.R. Spiegel, H.G.M van Haalen, N.J. de Wit, P.D. Siersema, and M.G.H. van Oijen

Patient-Reported Outcomes

- 778 Health Utility Assessment Using EQ-5D among Caregivers of Children with Autism**

Rahul Khanna, Krutika Jariwala, and John P. Bentley

TABLE OF CONTENTS - continued

- 789 Development and Initial Validation of the NCCN/FACT Symptom Index for Advanced Kidney Cancer**
Nan E. Rothrock, Sally E. Jensen, Jennifer L. Beaumont, Amy P. Abernethy, Paul B. Jacobsen, Karen Syrjala, and David Cella
- Preference-Based Assessments**
- 797 Willingness to Pay for Diagnostic Technologies: A Review of the Contingent Valuation Literature**
Pei-Jung Lin, Michael J. Cangelosi, David W. Lee, and Peter J. Neumann
- 806 Does the Process of Deliberation Change Individuals' Health State Valuations? An Exploratory Study Using the Person Trade-Off Technique**
Suzanne Robinson and Stirling Bryan
- 814 Italian Population-Based Values of EQ-5D Health States**
Luciana Scalone, Paolo A. Cortesi, Roberta Ciampichini, Andrea Belisari, Lucia S. D'Angiolella, Giancarlo Cesana, and Lorenzo G. Mantovani
- 823 Association between Health-Related Quality of Life and Body Mass After Adjustable Gastric Banding: A Nonlinear Approach**
Vincent W. Lin, Edwin S. Wong, Andrew Wright, David R. Flum, Louis P. Garrison Jr., Rafael Alfonso-Cristancho, and Sean D. Sullivan
- Comparative Effectiveness Research/Health Technology Assessment (HTA)**
- 830 Reviewing the Evidence to Inform the Population of Cost-Effectiveness Models within Health Technology Assessments**
Eva Kaltenthaler, Paul Tappenden, and Suzy Paisley
- 837 Updating the Canadian Hemophilia Outcomes–Kids Life Assessment Tool (CHO-KLAT Version_{2.0})**
Nancy L. Young, Cindy Wakefield, Tricia A. Burke, Randi Ray, Patricia J. McCusker, and Victor Blanchette
- Health Policy Analysis**
- 842 Which Is More Valuable, Longer Survival or Better Quality of Life? Israeli Oncologists' and Family Physicians' Attitudes Toward the Relative Value of New Cancer and Congestive Heart Failure Interventions**
Dan Greenberg, Ariel Hammerman, Shlomo Vinker, Adi Shani, Yuval Yermiah, and Peter J. Neumann
- METHODOLOGICAL ARTICLES**
- 848 Validating and Improving the Reliability of the EORTC QLQ-C30 Using a Multidimensional Rasch Model**
Ching-Lin Shih, Chien-Hung Chen, Ching-Fan Sheu, Hui-Chu Lang, and Ching-Lin Hsieh
- SYSTEMATIC REVIEWS**
- 855 How Should We Deal with Patient Heterogeneity in Economic Evaluation: A Systematic Review of National Pharmacoeconomic Guidelines**
Bram L.T. Ramaekers, Manuela A. Joore, and Janneke P.C. Grutters
- 863 Impact of Interventions on Medication Adherence and Blood Pressure Control in Patients with Essential Hypertension: A Systematic Review by the ISPOR Medication Adherence and Persistence Special Interest Group**
Femida H. Gwadry-Sridhar, Elizabeth Manias, Lincy Lal, Maribel Salas, Dyfrig A. Hughes, Alexandria Ratzki-Leewing, and Maja Grubisic
- 872 Efficacy, Patient-Reported Outcomes (PROs), and Tolerability of the Changing Therapeutic Landscape in Patients with Metastatic Prostate Cancer (MPC): A Systematic Literature Review**
Brian S. Seal, Carl V. Asche, Katarzyna Puto, and Pamela D. Allen

TABLE OF CONTENTS - continued

891 A Systematic Literature Review of Psychosocial and Behavioral Factors Associated with Initial Medication Adherence: A Report of the ISPOR Medication Adherence & Persistence Special Interest Group

John E. Zeber, Elizabeth Manias, Allison F. Williams, David Hutchins, Waka A. Udezi, Craig S. Roberts, Andrew M. Peterson, and ISPOR Medication Adherence Good Research Practices Working Group

POLICY PERSPECTIVE

901 Deciding Which Drugs Get Onto the Formulary: A Value-Based Approach

Raymond J. Seigfried, Teresa Corbo, Mitchell T. Saltzberg, Jeffrey Reitz, and Dean A. Bennett

906 Erratum

I Instructions for Authors